ABL001 (asciminib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABL001 (asciminib), covering 2026-01-09 to 2026-01-09. Get the full timeline:
Most recent: Clinical Trial Update: ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor [Phase 2]